title: Bufalin induces apoptosis and the G0/G1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis.
abstract: Most of the current medical treatments for endometriosis aim to down-regulate the estrogen activity. However, a high recurrence rate after medical treatments has been the most significant problem. Bufalin is a major digoxin-like immunoreactive component isolated from the skin and parotid venom glands of toad and is considered an apoptosis-inducing agent. To apply bufalin to the medical treatment of endometriosis, we investigated the effects of this agent on the cell proliferation and apoptosis of cultured ovarian endometriotic cyst stromal cells (ECSC) by a modified methylthiazoletetrazolium (MTT) assay, a 5-bromo-2'-deoxyuridine (BrdU) incorporation assay and internucleosomal DNA fragmentation assays. The effect of bufalin on the cell cycle of ECSC was also determined by flow cytometry. The expression of apoptosis- and cell cycle-related molecules was also examined in ECSC using Western blot analysis. Bufalin significantly inhibited the cell proliferation and DNA synthesis of ECSC and induced apoptosis and the G0/G1 phase cell cycle arrest of these cells. The down-regulation of the cyclin A, Bcl-2, and Bcl-X(L) expression with the simultaneous up-regulation of the p21 and Bax expression, and caspase-9 activation was observed in ECSC after bufalin treatment. It is suggested that bufalin induces apoptosis of ECSC by simultaneously suppressing anti-apoptotic proteins and inducing pro-apoptotic proteins. Caspase-9-mediated cascade is involved in this mechanism. Therefore, bufalin could be used as a therapeutic agent for the treatment of endometriosis.
authors.affiliation: Department of Obstetrics and Gynecology, Oita University, Hasama-machi, Oita, Japan. nasu@med.oita-u.ac.jp
authors.forename: Kaei
authors.initials: K
authors.lastname: Nasu
authors.forename: Masakazu
authors.initials: M
authors.lastname: Nishida
authors.forename: Tami
authors.initials: T
authors.lastname: Ueda
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Takai
authors.forename: Sun
authors.initials: S
authors.lastname: Bing
authors.forename: Hisashi
authors.initials: H
authors.lastname: Narahara
authors.forename: Isao
authors.initials: I
authors.lastname: Miyakawa
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D002018:Bufanolides / Q000494:pharmacology* / Q000627:therapeutic use; D002453:Cell Cycle / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004715:Endometriosis / Q000188:drug therapy*; D004717:Endometrium / Q000187:drug effects / Q000473:pathology*; D005260:Female; D016193:G1 Phase / Q000187:drug effects; D006801:Humans; D017697:Premenopause; D012016:Reference Values; D016192:Resting Phase, Cell Cycle / Q000187:drug effects; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors; D017154:Stromal Cells / Q000187:drug effects / Q000473:pathology*
chemical_list: D002018:Bufanolides; D000254:Sodium-Potassium-Exchanging ATPase; C022777:bufalin